Outset Medical announced today that it received FDA 510(k) clearance for its next-generation Tablo hemodialysis platform.
Zacks Investment Research on MSN
OM stock gains on FDA clearance for next-gen Tablo dialysis system
Outset Medical, Inc. OM recently announced that its next-generation Tablo hemodialysis system has received 510(k) clearance, ...
Medical Device Network on MSN
Outset Medical secures FDA clearance for Tablo haemodialysis system
Outset Medical plans to begin shipping the updated platform during the second quarter of 2026.
Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standardsSAN JOSE, Calif., Jan. 27, 2026 ...
Investing.com -- Outset Medical Inc (NASDAQ:OM) stock jumped 9% in premarket trading Tuesday after the medical technology company announced FDA clearance for its next-generation Tablo dialysis ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from ASN Kidney Week, Michael Aragon, MD, the chief medical officer of Outset Medical, ...
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis with its Tablo® Hemodialysis System, today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results